FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
Wall Street is divided on Capricor’s FDA approval prospects, with Oppenheimer betting on a favorable decision and significant upside in the stock price, while Roth Capital sees only a 25% chance of approval.